About Ascendia Pharmaceutical Solutions
Ascendia Pharmaceutical Solutions is a contract development and manufacturing organization for pharmaceutical and biotechnology companies. It provides pre-formulation, formulation development, analytical testing, ICH stability studies, and cGMP manufacturing from discovery through commercialization. Its work covers injectable, oral, topical, sterile, and non-sterile dosage forms for small molecules, biologics, gene delivery products, and marketed drugs. Four technology platforms use nano-emulsions, lipid nanoparticles, amorphous solid dispersions, and nanosized particles to address solubility, dissolution, bioavailability, and controlled-delivery challenges.
Jingjun “Jim” Huang founded Ascendia in 2012 and serves as CEO. Robert Bloder is chief commercial officer, while Beverly Langevin is vice president of formulation development and project management. By December 2024, the North Brunswick team had grown beyond 50 professionals. Its 60,000-square-foot facility houses cleanrooms and manufacturing suites for sterile and non-sterile work. The business adopted the Ascendia Pharmaceutical Solutions name in December 2024 to reflect its wider development and manufacturing services.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | Jul 24, 2026amended Nov 6, 2026 | $4,084,536fully sold | 3 | $1.3M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| May 22, 2025 | Jun 4, 2025 | $2,500,000fully sold | 9 | $277K | EquityRule 506(b) | Form D ↗ |
| Sep 30, 2024 | Oct 11, 2024 | $2,500,638fully sold | 2 | $1.2M | EquityRule 506(b) | Form D ↗ |
| Jul 1, 2022 | Jul 13, 2022 | $2,499,945fully sold | 2 | $1.2M | EquityRule 506(b) | Form D ↗ |
| Apr 7, 2021 | Apr 20, 2021 | $4,999,999of $9.9M target | 2 | $2.4M | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $16,585,118 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Ascendia Pharmaceutical Solutions
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Apr 8, 2021 | Growth equity investment | Undisclosed | Signet Healthcare Partners (lead) | PR Newswire release ↗ |
Why Investors Backed Ascendia Pharmaceutical Solutions
Ascendia sells formulation, analytical, stability, and manufacturing services to pharmaceutical and biotechnology companies. Its four proprietary platforms address difficult drug-delivery problems. A 2021 growth investment financed a facility expansion. The business later adopted the Ascendia Pharmaceutical Solutions brand as its services broadened.
The problem it targets
Poor water solubility can create dissolution and bioavailability problems across drug development. Small-scale formulations also present challenges for pharmaceutical companies. Ascendia focuses on those problems for preclinical candidates, clinical programs, and marketed products. Huang's research centers on poorly water-soluble drugs and controlled delivery.
What the product does
EmulSol produces oil-in-water nano-emulsions. LipidSol encapsulates small and large molecules in lipid nanoparticles. AmorSol uses amorphous solid dispersions to improve dissolution, while NanoSol creates nanosized drug particles with more surface area. Ascendia pairs these platforms with formulation, analytical, stability, and clinical-batch manufacturing services. It makes injectable materials, tablets, and capsules. The facility also supports sterile and non-sterile products, biologics, complex dosage forms, 505(b)(2) programs, over-the-counter products, and nutraceuticals.
Progress so far
Ascendia performs all formulation development and manufacturing work in the United States. Its North Brunswick facility includes ISO 5 and ISO 7 cleanrooms plus ISO 8 manufacturing suites. It has four patented technologies and made a fastest-growing private-company list four straight years. The business posted twofold growth over the prior two years.
Who backs it
Signet Healthcare Partners made a growth equity investment in April 2021. Signet is a New York firm focused on healthcare investments. Ascendia earmarked the proceeds for facility expansion. The transaction added Signet managing director James Gale and pharmaceutical executive Theron Odlaug to Ascendia's board. Wombat Capital Markets advised Ascendia. Sills Cummis & Gross represented Ascendia, while Sheppard Mullin represented Signet.
How the market is moving
Ascendia linked its 2021 facility expansion to growing sector demand. It expected the added footprint and capacity to meet production needs across early and late drug development. By 2024, its services reached from early formulation through GMP manufacturing and commercialization. The rebrand reflected that broader scope.
We wrote this summary from public statements by Ascendia Pharmaceutical Solutions and its investors. It is not investment advice.
Ascendia Pharmaceutical Solutions in the News
Leadership Team
Executive officers and directors listed on Ascendia Pharmaceutical Solutions's Form D filed Nov 6, 2026.
Earlier filings also listed Colin Foster (director, last listed Jul 2022).